Catia Marzolini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3502737/publications.pdf

Version: 2024-02-01

81	2,172	279487	253896
papers	citations	23 h-index	43 g-index

85	85	85	2455
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 2003, 73, 20-30.	2.3	231
2	Prevalence of comedications and effect of potential drugâ€“drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 2010, 15, 413-423.	0.6	172
3	Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 2011, 66, 2107-2111.	1.3	131
4	Recommendations for the Management of Drugâ€“Drug Interactions Between the <scp>COVID</scp>â€19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clinical Pharmacology and Therapeutics, 2022, 112, 1191-1200.	2.3	122
5	The challenge of HIV treatment in an era of polypharmacy. Journal of the International AIDS Society, 2020, 23, e25449.	1.2	107
6	Cobicistat versus ritonavir boosting and differences in the drugâ€“drug interaction profiles with co-medications. Journal of Antimicrobial Chemotherapy, 2016, 71, 1755-1758.	1.3	102
7	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	0.9	69
8	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2014, 1, ofu040.	0.4	61
9	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Medicine, 2022, 23, 849-858.	1.0	57
10	Polypharmacy and Drugâ€“Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. Clinical Infectious Diseases, 2020, 71, 353-362.	2.9	52
11	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	50
12	Pharmacokinetics and Drugâ€“Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine. Clinical Pharmacokinetics, 2021, 60, 835-853.	1.6	50
13	Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. Clinical Pharmacokinetics, 2019, 58, 483-501.	1.6	48
14	Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. Clinical Pharmacokinetics, 2013, 52, 583-592.	1.6	47
15	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. Journal of Antimicrobial Chemotherapy, 2020, 75, 3084-3086.	1.3	43
16	Polypharmacy, Drugâ€“Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.4	38
17	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genetics in Medicine, 2016, 18, 814-822.	1.1	36
18	Prescribing Nirmatrelvirâ€“Ritonavir: How to Recognize and Manage Drugâ€“Drug Interactions. Annals of Internal Medicine, 2022, 175, 744-746.	2.0	35

#	Article	IF	Citations
19	A Comprehensive Framework for Physiologicallyâ€Based Pharmacokinetic Modeling in Matlab. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 444-459.	1.3	32
20	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs in R and D, 2021, 21, 9-27.	1.1	31
21	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. Journal of Antimicrobial Chemotherapy, 2020, 75, 3417-3424.	1.3	30
22	Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS ONE, 2017, 12, e0173509.	1.1	29
23	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics, 2020, 59, 383-401.	1.6	29
24	Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clinical Pharmacokinetics, 2019, 58, 1553-1565.	1.6	24
25	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€2017. Journal of the International AIDS Society, 2019, 22, e25339.	1.2	24
26	Development and validation of a multiplex UHPLCâ€MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. Journal of Mass Spectrometry, 2020, 55, e4506.	0.7	22
27	Global Genomic Analysis of SARS-CoV-2 RNA Dependent RNA Polymerase Evolution and Antiviral Drug Resistance. Microorganisms, 2021, 9, 1094.	1.6	21
28	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21
29	The Brain Entry of HIV-1 Protease Inhibitors Is Facilitated When Used in Combination. Molecular Pharmaceutics, 2013, 10, 2340-2349.	2.3	20
30	Prescribing issues in elderly individuals living with HIV. Expert Review of Clinical Pharmacology, 2019, 12, 643-659.	1.3	20
31	COVIDâ€19 treatment in patients with comorbidities: Awareness of drugâ€drug interactions. British Journal of Clinical Pharmacology, 2021, 87, 212-213.	1.1	20
32	Physiologically Based Pharmacokinetic Modeling to Predict Drugâ€“Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clinical Pharmacokinetics, 2017, 56, 409-420.	1.6	18
33	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. Aids, 2020, 34, 103-108.	1.0	18
34	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
35	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology, 2020, 71, 1831-1844.	3.6	16
36	Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. British Journal of Clinical Pharmacology, 2017, 83, 2835-2838.	1.1	15

#	Article	IF	Citations
37	Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVIDâ€19 Patients. Clinical Pharmacology and Therapeutics, 2022, 111, 579-584.	2.3	15
38	Prescribing issues in older adults living with HIV: thinking beyond drugâ€“drug interactions with antiretroviral drugs. Therapeutic Advances in Drug Safety, 2019, 10, 204209861988012.	1.0	14
39	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. Journal of Antimicrobial Chemotherapy, 2021, 76, 758-764.	1.3	14
40	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Aids, 2015, 29, 193-200.	1.0	13
41	Physiologicallyâ€Based Pharmacokinetic Modeling to Support the Clinical Management of Drugâ€“Drug Interactions With Bictegravir. Clinical Pharmacology and Therapeutics, 2021, 110, 1231-1239.	2.3	13
42	Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. Clinical Microbiology and Infection, 2022, 28, 1044-1046.	2.8	13
43	Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. AIDS Research and Human Retroviruses, 2019, 35, 985-998.	0.5	12
44	Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. British Journal of Clinical Pharmacology, 2021, 87, 458-470.	1.1	12
45	Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1203-1217.	1.5	11
46	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20.	1.9	10
47	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121733.	1.2	10
48	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drugâ€Drug Interaction Magnitudes in the Elderly. Clinical Pharmacology and Therapeutics, 2021, 109, 471-484.	2.3	10
49	Drugâ€“Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?. Clinical Pharmacokinetics, 2020, 59, 1217-1236.	1.6	9
50	Prevalence of Potential Drugâ€“Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. Clinical Infectious Diseases, 2021, 73, e2145-e2152.	2.9	9
51	Fluvoxamine for the treatment of COVID-19. The Lancet Global Health, 2022, 10, e331.	2.9	9
52	Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV. Clinical Pharmacokinetics, 2022, 61, 619-635.	1.6	9
53	Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. Journal of Antimicrobial Chemotherapy, 2017, 72, 2574-2577.	1.3	8
54	Real-life management of drugâ€“drug interactions between antiretrovirals and statins. Journal of Antimicrobial Chemotherapy, 2020, 75, 1972-1980.	1.3	8

#	Article	IF	Citations
55	Physiologicallyâ€Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV. Clinical Pharmacology and Therapeutics, 2021, 109, 1025-1029.	2.3	8
56	Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. Aids, 2018, 32, 1903-1905.	1.0	7
57	HIV and Aging â€“ Perhaps Not as Dramatic as We Feared?. Gerontology, 2018, 64, 446-456.	1.4	7
58	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drugâ€“drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 2019, 85, 2022-2032.	1.1	7
59	Cobicistat: A case of mislabelled drugâ€drug interaction risk?. British Journal of Clinical Pharmacology, 2020, 86, 834-836.	1.1	7
60	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 492-499.	1.3	7
61	Etravirine: a good option for concomitant use with chemotherapy for Hodgkinâ€™s lymphoma. International Journal of STD and AIDS, 2015, 26, 212-214.	0.5	5
62	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 2020, 224, 1198-1208.	1.9	5
63	Influence of Drugâ€“Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 2020, 59, 1037-1048.	1.6	5
64	Coronary Artery Diseaseâ€“Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, 1597-1604.	2.9	5
65	Magnitude of Drugâ€“Drug Interactions in Special Populations. Pharmaceutics, 2022, 14, 789.	2.0	5
66	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 379-390.	1.6	4
67	Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipientâ€”a case report and review of the literature. AIDS Research and Therapy, 2021, 18, 56.	0.7	4
68	Dexamethasone is a dose-dependent perpetrator of drugâ€“drug interactions: implications for use in people living with HIV. Journal of Antimicrobial Chemotherapy, 2022, 77, 568-573.	1.3	4
69	Maternal antiretroviral prophylaxis and breastfeeding. Antiviral Therapy, 2012, 17, 1503-1506.	0.6	3
70	Mechanisms of Drug Interactions II: Transport Proteins. , 2018, , 49-85.		3
71	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. Journal of Antimicrobial Chemotherapy, 2019, 74, 2468-2470.	1.3	3
72	Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre. Global Cardiology Science & Practice, 2021, 2021, e202111.	0.3	3

#	Article	IF	Citations
73	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. Journal of Infectious Diseases, 2022, 225, 1581-1591.	1.9	3
74	Aging does not impact drug–drug interaction magnitudes with antiretrovirals. Aids, 2020, 34, 949-952.	1.0	2
75	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	0.8	2
76	Recognition and management of clinically significant drugâ€“drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2681-2689.	1.3	2
77	Sex-related pharmacokinetic differences with aging. European Geriatric Medicine, 2021, , 1.	1.2	2
78	Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19. Drug Safety, 2021, 44, 255-257.	1.4	1
79	Polypharmacy and risk of admission to hospital in people ageing with HIV: what is the contribution of drugâ€“drug interactions?. The Lancet Healthy Longevity, 2021, 2, e606-e607.	2.0	1
80	Drugâ€“Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. Clinical Pharmacokinetics, 2022, 61, 339-346.	1.6	1
81	Prescribing in COVIDâ€19 patients: Should we take into account inflammation?. British Journal of Clinical Pharmacology, 2021, 87, 719-721.	1.1	0